Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation.

已完结 20 由 long 发布于 2025/12/13 13:35:22

DOI:10.1002/cpt.70037
作者：Wangda Zhou,?Emily Bozenhardt,?Gregory E Alexander,?Matthew L Zierhut,?Samira Merali,?Antoinette Ajavon-Hartmann,?Peter Zannikos,?Hyunmoon Back,?EunYoung Suh,?Navin Goyal,?Mahesh N Samtani,?Alexei N P
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1002/cpt.70037

Wiley

Abstract：Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIB

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierMethyl-coenzyme M reductase